The EMPOWER-Lung 1 trial examined the efficacy and safety of cemiplimab in untreated advanced NSCLC with PD-L1 at least 50% and enrolled 68 (12.1%) patients with treated BM. This evidence concerns the gene CD274 and non-small cell lung carcinoma.